{"id":243,"date":"2026-08-20T10:30:00","date_gmt":"2026-08-20T10:30:00","guid":{"rendered":"https:\/\/makrolife-biotech.com\/blog\/?p=243"},"modified":"2026-07-24T13:45:48","modified_gmt":"2026-07-24T13:45:48","slug":"cosmetic-product-launch-timeline-eu","status":"publish","type":"post","link":"https:\/\/makrolife-biotech.com\/blog\/cosmetic-product-launch-timeline-eu\/","title":{"rendered":"Why Cosmetic Product Launches Get Delayed: A Practical EU Timeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Launching a cosmetic product in the European Union requires several connected workstreams:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>product development<\/li>\n\n\n\n<li>supplier documentation<\/li>\n\n\n\n<li>stability and microbiology<\/li>\n\n\n\n<li>safety assessment<\/li>\n\n\n\n<li>packaging<\/li>\n\n\n\n<li>claim substantiation<\/li>\n\n\n\n<li>PIF preparation<\/li>\n\n\n\n<li>CPNP notification<\/li>\n\n\n\n<li>production and distribution<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The individual activities are manageable. The difficulty is completing them in the correct order.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A product launch can be delayed even when every supplier completes its own task on time. One outdated formula, missing allergen declaration or late packaging change can invalidate work completed elsewhere.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How long does an EU cosmetic launch take?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">There is no universal timeline.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The duration depends on:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>formula complexity<\/li>\n\n\n\n<li>product type<\/li>\n\n\n\n<li>document completeness<\/li>\n\n\n\n<li>testing requirements<\/li>\n\n\n\n<li>packaging<\/li>\n\n\n\n<li>supplier response times<\/li>\n\n\n\n<li>claims<\/li>\n\n\n\n<li>target population<\/li>\n\n\n\n<li>product variants<\/li>\n\n\n\n<li>Responsible Person readiness<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">A simple, well-documented product may move quickly. A complex product with incomplete raw-material data, an untested preservation system or ambitious claims can require significantly more work.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The better planning question is not:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">How quickly can we get a CPSR?<\/p>\n<\/blockquote>\n\n\n\n<p class=\"wp-block-paragraph\">It is:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">When will the complete final product, its evidence and its documentation be ready for market placement?<\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\">Phase 1: Product concept and regulatory screening<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Before finalising the formula, define:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>intended product function<\/li>\n\n\n\n<li>target users<\/li>\n\n\n\n<li>application area<\/li>\n\n\n\n<li>frequency of use<\/li>\n\n\n\n<li>rinse-off or leave-on status<\/li>\n\n\n\n<li>target EU countries<\/li>\n\n\n\n<li>planned claims<\/li>\n\n\n\n<li>packaging format<\/li>\n\n\n\n<li>likely product classification<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This early review can identify whether a product risks falling into another regulatory category because of its composition, presentation or claims.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Common delay<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The marketing team develops medicinal, biocidal or therapeutic-style claims after the product has already been designed as a cosmetic.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Better approach<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Review the intended claims and product presentation before the development brief is approved.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Phase 2: Formula development and ingredient screening<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">During formulation, review:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>prohibited ingredients<\/li>\n\n\n\n<li>restricted ingredients<\/li>\n\n\n\n<li>permitted preservatives<\/li>\n\n\n\n<li>permitted colourants<\/li>\n\n\n\n<li>permitted UV filters<\/li>\n\n\n\n<li>allergen implications<\/li>\n\n\n\n<li>nanomaterials<\/li>\n\n\n\n<li>impurity concerns<\/li>\n\n\n\n<li>vulnerable-user considerations<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The safety assessment is easier when regulatory constraints are addressed during development instead of after formula freeze.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Common delay<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A restricted ingredient or concentration issue is identified only when the safety assessor receives the final formula.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Better approach<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Complete a preliminary regulatory and toxicological formula review before ordering pilot production.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Phase 3: Supplier-document collection<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Collect documents for every raw material.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The required package may include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>INCI and composition<\/li>\n\n\n\n<li>specification<\/li>\n\n\n\n<li>certificate of analysis<\/li>\n\n\n\n<li>safety data<\/li>\n\n\n\n<li>impurity profile<\/li>\n\n\n\n<li>allergen declaration<\/li>\n\n\n\n<li>fragrance documentation<\/li>\n\n\n\n<li>microbiological specification<\/li>\n\n\n\n<li>natural-origin information<\/li>\n\n\n\n<li>nanomaterial information<\/li>\n\n\n\n<li>toxicological information<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Common delay<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The formula is frozen, but suppliers take weeks to answer composition or impurity questions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Better approach<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Start document collection as soon as raw materials enter the development shortlist.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Phase 4: Formula freeze and version control<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Testing and assessment should refer to a controlled formula version.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Record:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>formula number<\/li>\n\n\n\n<li>version<\/li>\n\n\n\n<li>date<\/li>\n\n\n\n<li>supplier<\/li>\n\n\n\n<li>raw-material grade<\/li>\n\n\n\n<li>concentration<\/li>\n\n\n\n<li>manufacturing process<\/li>\n\n\n\n<li>batch identification<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Common delay<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A fragrance, preservative or viscosity modifier is changed after testing, but the previous reports continue to be used.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Better approach<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Create a formal change assessment for every post-freeze modification.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Phase 5: Testing strategy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Depending on the product, evidence may include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>stability testing<\/li>\n\n\n\n<li>microbiological-quality testing<\/li>\n\n\n\n<li>preservation-challenge testing<\/li>\n\n\n\n<li>compatibility testing<\/li>\n\n\n\n<li>chemical analysis<\/li>\n\n\n\n<li>packaging assessment<\/li>\n\n\n\n<li>claim-substantiation studies<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The test plan should be based on the product\u2019s risk and intended use.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Common delay<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Every available test is ordered without determining which regulatory question it should answer.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Better approach<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Classify tests as:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>required for the planned assessment<\/li>\n\n\n\n<li>recommended to reduce uncertainty<\/li>\n\n\n\n<li>optional for commercial or claim purposes<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Phase 6: Stability and packaging evaluation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Stability work should consider the actual packaging intended for market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Relevant observations may include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>appearance<\/li>\n\n\n\n<li>odour<\/li>\n\n\n\n<li>colour<\/li>\n\n\n\n<li>pH<\/li>\n\n\n\n<li>viscosity<\/li>\n\n\n\n<li>separation<\/li>\n\n\n\n<li>leakage<\/li>\n\n\n\n<li>container deformation<\/li>\n\n\n\n<li>product loss<\/li>\n\n\n\n<li>compatibility<\/li>\n\n\n\n<li>shelf-life indicators<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Common delay<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The product is tested in laboratory packaging while the final commercial container is still being selected.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Better approach<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Confirm the packaging system early enough for representative stability and compatibility work.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Phase 7: Microbiological assessment<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Water-containing cosmetics and products exposed to repeated consumer contact may require specific microbiological evidence.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Common delay<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The challenge test is planned only after the safety assessor requests it.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Better approach<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Assess the preservation strategy during development and reserve sufficient time for testing and any necessary reformulation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Phase 8: Claim-evidence planning<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Claims should be connected to appropriate evidence.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Possible evidence sources include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>scientific literature<\/li>\n\n\n\n<li>ingredient data<\/li>\n\n\n\n<li>instrumental tests<\/li>\n\n\n\n<li>in-vitro studies<\/li>\n\n\n\n<li>consumer studies<\/li>\n\n\n\n<li>clinical studies<\/li>\n\n\n\n<li>expert assessment<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">EU claims must comply with common criteria and be consistent with evidence in the PIF.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Common delay<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Packaging and campaign copy are approved before anyone confirms that the final product evidence supports the wording.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Better approach<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Create a claim-evidence matrix before artwork approval.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Phase 9: Cosmetic Product Safety Report<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The qualified safety assessor evaluates the complete product information and prepares Part B of the CPSR.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The EU requires the safety assessment and CPSR before the cosmetic product is placed on the market.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Common delay<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The assessor receives incomplete or inconsistent documents and must begin several rounds of questions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Better approach<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Perform a pre-assessment completeness check.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Phase 10: PIF compilation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Product Information File connects the safety report to the wider product documentation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">It includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>product description<\/li>\n\n\n\n<li>CPSR<\/li>\n\n\n\n<li>manufacturing method and GMP statement<\/li>\n\n\n\n<li>claim evidence where relevant<\/li>\n\n\n\n<li>animal-testing information required by the Regulation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The PIF must be kept current and retained for ten years after the final batch is placed on the market.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Common delay<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Files exist across multiple suppliers, inboxes and folders but have never been compiled into a controlled PIF.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Better approach<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Use one document index, clear ownership and controlled versioning.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Phase 11: Label and artwork approval<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Review the final artwork against:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>the approved formula<\/li>\n\n\n\n<li>CPSR warnings<\/li>\n\n\n\n<li>INCI information<\/li>\n\n\n\n<li>Responsible Person details<\/li>\n\n\n\n<li>product function<\/li>\n\n\n\n<li>nominal content<\/li>\n\n\n\n<li>durability information<\/li>\n\n\n\n<li>batch identification<\/li>\n\n\n\n<li>country of origin<\/li>\n\n\n\n<li>claim evidence<\/li>\n\n\n\n<li>market-language requirements<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Common delay<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The packaging order is placed before the CPSR and final ingredient review are complete.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Better approach<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Create a formal \u201cregulatory approved for print\u201d gate.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Phase 12: CPNP notification<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Responsible Person submits the required product information through CPNP.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The CPNP is a free EU notification system. A correctly notified product does not generally require additional national cosmetic notification, but notification itself is not a safety approval.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Common delay<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The team assumes that a manufacturer or consultant has already completed notification, but responsibility and access were never documented.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Better approach<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Assign one named owner and retain confirmation within the product file.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Phase 13: Final market-readiness review<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Before release, confirm that:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>the marketed formula matches the assessed formula<\/li>\n\n\n\n<li>the packaging matches the reviewed artwork<\/li>\n\n\n\n<li>all required tests are final<\/li>\n\n\n\n<li>the CPSR is signed<\/li>\n\n\n\n<li>the PIF is accessible<\/li>\n\n\n\n<li>CPNP is complete<\/li>\n\n\n\n<li>Responsible Person information is correct<\/li>\n\n\n\n<li>claims match the evidence<\/li>\n\n\n\n<li>product variants are correctly linked<\/li>\n\n\n\n<li>distributor information is current<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This final review prevents a technically completed project from becoming a non-compliant launch.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The most common causes of launch delays<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Missing supplier information<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Suppliers may provide marketing brochures but not the composition, impurity or toxicological data required for assessment.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Repeated formula changes<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Each late modification can affect testing, ingredient labelling, exposure and safety conclusions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Unclear variant strategy<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Brands underestimate how different fragrances, colours or actives affect the assessment.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Late packaging decisions<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The final container can affect stability, contamination risk, compatibility and label space.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Unsupported claims<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The evidence does not match the strength or wording of the marketing statement.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Fragmented responsibility<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No one manages dependencies between the brand, manufacturer, laboratory, assessor and Responsible Person.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Unrealistic launch dates<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Commercial deadlines are announced before technical lead times have been assessed.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">A practical planning sequence<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The most efficient order is generally:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Product concept and claim review<\/li>\n\n\n\n<li>Preliminary formula screening<\/li>\n\n\n\n<li>Supplier-document collection<\/li>\n\n\n\n<li>Formula freeze<\/li>\n\n\n\n<li>Testing and evidence programme<\/li>\n\n\n\n<li>Packaging compatibility<\/li>\n\n\n\n<li>Safety assessment<\/li>\n\n\n\n<li>PIF and label review<\/li>\n\n\n\n<li>CPNP notification<\/li>\n\n\n\n<li>Final release<\/li>\n\n\n\n<li>Post-market monitoring<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Several activities can overlap, but their dependencies must be understood.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How Makrolife can support launch planning<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Makrolife can create a coordinated testing and safety-assessment roadmap covering:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>document requirements<\/li>\n\n\n\n<li>formula review<\/li>\n\n\n\n<li>testing priorities<\/li>\n\n\n\n<li>supplier-data gaps<\/li>\n\n\n\n<li>safety assessment<\/li>\n\n\n\n<li>CPSR and PIF preparation<\/li>\n\n\n\n<li>label and claim consistency<\/li>\n\n\n\n<li>CPNP coordination<\/li>\n\n\n\n<li>result interpretation<\/li>\n\n\n\n<li>project milestones<\/li>\n\n\n\n<li>post-launch updates<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The purpose is not simply to accelerate every task. It is to prevent avoidable repetition, reprinting and retesting.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Build the timeline before announcing the launch date<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The fastest cosmetic project is rarely the one that skips steps. It is the one that identifies dependencies early and assigns clear responsibility.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Request a coordinated EU Cosmetic Launch Roadmap from Makrolife.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Launching a cosmetic product in the European Union requires several connected workstreams: The individual activities are manageable. The difficulty is completing them in the correct order. A product\u2026<\/p>\n","protected":false},"author":2,"featured_media":244,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,9],"tags":[19,40,14,45],"class_list":["post-243","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-beauty-and-supplements","category-regulatory","tag-cosmetics","tag-cpsr","tag-eu","tag-eu-cosmetics-launch"],"_links":{"self":[{"href":"https:\/\/makrolife-biotech.com\/blog\/wp-json\/wp\/v2\/posts\/243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makrolife-biotech.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makrolife-biotech.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makrolife-biotech.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/makrolife-biotech.com\/blog\/wp-json\/wp\/v2\/comments?post=243"}],"version-history":[{"count":1,"href":"https:\/\/makrolife-biotech.com\/blog\/wp-json\/wp\/v2\/posts\/243\/revisions"}],"predecessor-version":[{"id":245,"href":"https:\/\/makrolife-biotech.com\/blog\/wp-json\/wp\/v2\/posts\/243\/revisions\/245"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makrolife-biotech.com\/blog\/wp-json\/wp\/v2\/media\/244"}],"wp:attachment":[{"href":"https:\/\/makrolife-biotech.com\/blog\/wp-json\/wp\/v2\/media?parent=243"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makrolife-biotech.com\/blog\/wp-json\/wp\/v2\/categories?post=243"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makrolife-biotech.com\/blog\/wp-json\/wp\/v2\/tags?post=243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}